Navigation Links
Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
Date:9/17/2007

Next-Generation Once-Daily CCR5 Antagonist Designed to Block HIV Infection

of Immune System Cells

KENILWORTH, N.J., Sept. 17 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announced that it has initiated two large Phase III clinical studies with vicriviroc, its investigational CCR5 antagonist, administered once-daily as a single 30 mg tablet in combination with an optimized background therapy that must include a protease inhibitor boosted by ritonavir in adult treatment-experienced HIV patients with R5-type virus only. Vicriviroc is a next-generation extracellular inhibitor of HIV infection designed to block entry of infectious virions into uninfected CD4 cells via antagonism of the CCR5 co-receptor.

The vicriviroc Phase III clinical program builds upon previous studies in HIV treatment-experienced patients, including a Phase II study (ACTG 5211) in which vicriviroc demonstrated potent and sustained viral suppression through 48 weeks of therapy.(1)

The two Phase III studies, known as VICTOR-E3 and VICTOR-E4 (Vicriviroc in Combination Treatment with an Optimized Antiretroviral Therapy Regimen in HIV- Infected Treatment-Experienced Subjects), will evaluate the virologic benefit of adding vicriviroc 30 mg once daily to an optimized background therapy compared to a control group receiving new optimized background therapy alone. The studies will also evaluate the safety and tolerability of vicriviroc compared to placebo. The optimized background therapy must include at least two drugs that are active, based on susceptibility testing. Patients coinfected with hepatitis C may be included in the studies and there are no exclusions of commonly prescribed drug
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Schering-Plough Announces Hepatitis C Data Presentations at Digestive Disease Week (DDW) 2007 Annual Meeting
2. Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C
3. Schering-Plough Announces Presentation of Phase II Trial Results for Novel Oral Thrombin Receptor Antagonist at the 2007 Annual Meeting of The American College of Cardiology/i2 Summit
4. Malvern initiates European user group meetings for chemical imaging
5. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
6. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... -- Among 1,000 U.S. consumers, the majority (65.3 percent) ... surveyed are aware of prescription savings cards, and just ... to findings from a new survey released today by ... improving the health and well-being of individuals, families and ... and women, ages 21 and older, on their spending, ...
(Date:8/4/2015)... 4, 2015  Ironshore Pharmaceuticals & Development, Inc. ... a company specializing in personalized medicine, to participate ... designed to evaluate the safety and efficacy of ... Attention-deficit/hyperactivity disorder (ADHD). This is Restore,s second clinical ... originally partnered with Ironshore in 2014 and continues ...
(Date:8/3/2015)...  Landauer, Inc. (NYSE: LDR ), a recognized ... outsourced medical physics services and high quality medical consumable ... the fiscal third quarter 2015 after the market close ... Company will also host a conference call for investors ... Time (10:00 a.m. Eastern Time). Investors may access the ...
Breaking Medicine Technology:New Study Finds Consumers are Leaving Money at the Pharmacy 2New Study Finds Consumers are Leaving Money at the Pharmacy 3Restore Health Secures Another Clinical Trial with Ironshore Pharmaceuticals & Development 2Landauer, Inc. Announces Date And Time For Announcement Of Fiscal Third Quarter 2015 Results And Conference Call 2
... Schering-Plough,Corporation (NYSE: SGP ) and The ... of Baltimore today announced results of the ... Eptifibatide to,Arrest the Reactivity of Platelets) study, ... IIIa inhibitor, significantly inhibited,platelet aggregation when added ...
... Immtech Pharmaceuticals,Inc. (Amex: IMM ) today ... a,scientific consortium led by the University of North ... The Bill & Melinda Gates Foundation,(the "Gates Foundation"), ... and leishmania. This grant is part of the ...
Cached Medicine Technology:Addition of INTEGRILIN(R) (Eptifibatide) to Bivalirudin Plus Standard of Care Inhibits Platelet Aggregation in Patients Undergoing Elective Coronary Stenting 2Addition of INTEGRILIN(R) (Eptifibatide) to Bivalirudin Plus Standard of Care Inhibits Platelet Aggregation in Patients Undergoing Elective Coronary Stenting 3Addition of INTEGRILIN(R) (Eptifibatide) to Bivalirudin Plus Standard of Care Inhibits Platelet Aggregation in Patients Undergoing Elective Coronary Stenting 4Addition of INTEGRILIN(R) (Eptifibatide) to Bivalirudin Plus Standard of Care Inhibits Platelet Aggregation in Patients Undergoing Elective Coronary Stenting 5Immtech Receives $5.1 Million to Further African Sleeping Sickness Clinical Trials 2Immtech Receives $5.1 Million to Further African Sleeping Sickness Clinical Trials 3
(Date:8/4/2015)... , ... August 04, 2015 , ... ... manufacturing, label design, product packaging, and fulfillment services, joined over 200 other Long ... event was held on Tuesday, July 28th at Jones Beach State Park in ...
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... ... complete with full examination now offered by the world renowned Beverly Hills ... aesthetic facial appearance through cosmetic surgery techniques helps individuals to achieve an outer ...
(Date:8/4/2015)... ... August 04, 2015 , ... Montclair State University and Atlantic Health System ... its kind in New Jersey, which starting this Fall will help prepare those entering ... partnered with Atlantic Health System, one of the largest health care organizations in New ...
(Date:8/4/2015)... Denver, CO (PRWEB) , ... August 04, 2015 ... ... for skilled nursing homes and other long-term care facilities, today announced details of ... (QAPI) for nursing homes and centers. , Providigm’s QAPI Accreditation program , ...
(Date:8/4/2015)... ... August 04, 2015 , ... Sin City Gallery is delighted ... a diverse group of exceptionally talented female artists. The exhibition premieres at ... September 25-27, 2015 in Downtown Las Vegas. Curated by gallery director Dr. Laura ...
Breaking Medicine News(10 mins):Health News:NutraScience Labs "Steps Up" to the 2015 Marcum Workplace Challenge 2Health News:Beverly Hills Surgeon, Dr. Paul Nassif, is Now Offering Personal Consultations with Full Examinations for Facial Plastic Surgeries 2Health News:Beverly Hills Surgeon, Dr. Paul Nassif, is Now Offering Personal Consultations with Full Examinations for Facial Plastic Surgeries 3Health News:Atlantic Health System & Montclair State University Launch Graduate Program in Arts & Health 2Health News:Atlantic Health System & Montclair State University Launch Graduate Program in Arts & Health 3Health News:Nursing Homes Achieving New Advanced Accreditation See Improved Measures of Quality, Better Occupancy Rates 2Health News:Nursing Homes Achieving New Advanced Accreditation See Improved Measures of Quality, Better Occupancy Rates 3Health News:Sin City Gallery Rocks Life Is Beautiful Festival with INTIMATELY FEMALE at Art Motel 2Health News:Sin City Gallery Rocks Life Is Beautiful Festival with INTIMATELY FEMALE at Art Motel 3Health News:Sin City Gallery Rocks Life Is Beautiful Festival with INTIMATELY FEMALE at Art Motel 4
... March 12 Jordan Lapides, a 54-year-old teacher of Spirituality ... And Spiritual Development in Pennsylvania, was recently challenged by one ... his weight problem. Lapides took up the challenge and ... has sparked a media frenzy. He has appeared on television, ...
... the counter treatment for,chronic and acute wounds. The revolutionary new product ... prevents scar formation. , ... Bellwood, IL (PRWEB) March ... on revolutionary technology in the healing of wounds. Based on a ...
... deployed as the electronic data capture and clinical data management system ... , ... New Haven, CT (PRWEB) March 12, 2009 ... the OpenClinica clinical data capture and management software for the Parkinson,s ...
... Colon(R) Educational Exhibit to Detroit Science Center, March 13 ... March 11 Colorectal cancer (cancer that begins either ... common cancer in both men and women in the ... 148,810 Americans were diagnosed with colorectal cancer in 2008, ...
... begin with one altruistic living donor, study explains, , , ... healthy young man stepped forward, willing to give one ... later, 10 people had received new kidneys from that ... started the first nonsimultaneous, extended altruistic-donor (NEAD) chain. The ...
... Salmonella bacteria research from two recent NASA ... bacteria,s disease-causing potential that hold promise for ... Earth.(Logo: http://www.newscom.com/cgi-bin/prnh/20081007/38461LOGO )Salmonella is ... related illnesses. According to the Centers for ...
Cached Medicine News:Health News:54-Year-Old Psychology Teacher Loses 155 Pounds In 10 Months By Applying His Own Teachings To Himself 2Health News:Wound Be Gone: Quickly Gaining Strong Support from Clinician Experts in the Field of Wound Healing 2Health News:Institute for Neurodegenerative Disorders Deploys OpenClinica EDC solution for Large Parkinson's Study 2Health News:Institute for Neurodegenerative Disorders Deploys OpenClinica EDC solution for Large Parkinson's Study 3Health News:Keep Your Rear in the Clear 2Health News:Keep Your Rear in the Clear 3Health News:Keep Your Rear in the Clear 4Health News:Living Kidney Donation Chains May Help More Get Transplants 2Health News:Living Kidney Donation Chains May Help More Get Transplants 3Health News:Space Research May Help Explain Salmonella Illness 2Health News:Space Research May Help Explain Salmonella Illness 3
... technology is the first and ... patented digital sensor all ... sensor. Dolphin ONE™ sensors both ... in the sensor, resulting in ...
Immersion Oil, 21,000 cs...
Immersion Oil, 1,250 cs...
... the standard - the ones to compare with, ... consistently led in the development and standardization of ... the record: , When the FDA set general ... Vitro Diagnostics in the 1970's, Cargille Immersion Oils ...
Medicine Products: